peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

ghrelin agonist

Relamorelin

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

Relamorelin is described as a long-acting analogue of acyl-ghrelin (a structural/functional mimic designed for longer duration of action).

Sources for this introduction: [1]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

Relamorelin is described as a long-acting analogue of acyl-ghrelin (a structural/functional mimic designed for longer duration of action).

Sources[1]pubmedGhrelin and relamorelin counteract hypoglycemia in mice engrafted with congenital hyperinsulinism stem cell-derived islets.We tested acyl-ghrelin identified in our in vitro experiments and its long-acting analogue relamorelin in these mice.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “We tested acyl-ghrelin identified in our in vitro experiments and its long-acting analogue relamorelin in these mice.”

    Ghrelin and relamorelin counteract hypoglycemia in mice engrafted with congenital hyperinsulinism stem cell-derived islets. · RESULTS

    pubmed:42556326:8bda5d8865cb:8bda5d8865cb

How does it work?

Target, response, and disposition.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

What has been studied?

What the evidence says.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, effect, interaction, mechanism, regulatory, safety
  • 5 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (2), assurance_score_below_0.72 (3), current_regulatory_source_required (1), extraction_ambiguity (5), high_risk_requires_regulatory_or_two_independent_sources (3), no_direct_support (5)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Ghrelin and relamorelin counteract hypoglycemia in mice engrafted with congenital hyperinsulinism stem cell-derived islets. ↗

    pubmed · published 2026-07-20 · retrieved 2026-08-21T17:03:42Z

Publication history and provenance

Version 2 · Automated assessment · 2026-08-21T17:03:42Z

669684077ac7367cd0c4dcff0d5160a39df971df268fc794e89321c724c8c5fd